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Int J Geriatr Psychiatry. 2018;33:561–575.Objective: The aim of this review is to determine whether automated computerised tests
accurately identify patients with progressive cognitive impairment and, if so, to investigate their
role in monitoring disease progression and/or response to treatment.
Methods: Six electronic databases (Medline, Embase, Cochrane, Institute for Scientific Infor-
mation, PsycINFO, and ProQuest) were searched from January 2005 to August 2015 to identify
papers for inclusion. Studies assessing the diagnostic accuracy of automated computerised tests
for mild cognitive impairment (MCI) and early dementia against a reference standard were
included. Where possible, sensitivity, specificity, positive predictive value, negative predictive
value, and likelihood ratios were calculated. The Quality Assessment of Diagnostic Accuracy
Studies tool was used to assess risk of bias.
Results: Sixteen studies assessing 11 diagnostic tools for MCI and early dementia were
included. No studies were eligible for inclusion in the review of tools for monitoring progressive
disease and response to treatment. The overall quality of the studies was good. However, the
wide range of tests assessed and the non‐standardised reporting of diagnostic accuracy outcomes
meant that statistical analysis was not possible.
Conclusion: Some tests have shown promising results for identifying MCI and early demen-
tia. However, concerns over small sample sizes, lack of replicability of studies, and lack of evi-
dence available make it difficult to make recommendations on the clinical use of the
computerised tests for diagnosing, monitoring progression, and treatment response for MCI
and early dementia. Research is required to establish stable cut‐off points for automated
computerised tests used to diagnose patients with MCI or early dementia.
KEYWORDS
ageing, Alzheimer disease, automated tests, computerised tests, dementia, diagnosis, MCI, monitoring1 | INTRODUCTION
Cognitive impairment in dementia is a growing public health concern.1
It is a distinctive characteristic of all dementias, and its timely assess-
ment is a crucial and essential element in the diagnosis of dementia.2
This is because some causes of dementia are treatable and are fully- - - - - - - - - - - - - - - - - - - - - - - - - - -
e Creative Commons Attribution Li
atric Psychiatry Published by John
iverpool.
SPERO CRD42015025410.or partially reversible, including dementias caused by vitamin B12 defi-
ciency,3 side effects of medications,4 metabolic abnormality, and cer-
tain brain tumours.5 There is evidence from the United States that
early recognition and treatment of dementia may delay the subsequent
need for nursing home care and may reduce the risk of misdiagnosis
and inappropriate management and reduce responsibilities for carers.6
Obtaining accurate incidence and prevalence figures for MCI is
difficult since people with cognitive impairment may go undiagnosed.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Key points
• Timely diagnosis of mild cognitive impairment (MCI) and
early dementia is important for good prognosis and
effective management.
• A number of automated tests for diagnosing and
monitoring progression of cognitive impairment have
been developed, which need to be used in conjunction
with clinical assessment.
• The overall quality and quantity of the available
evidence are insufficient to make recommendations on
the clinical use of these automated computerised tests.
• Further research is required to examine the cut‐off
points for different populations in automated tests for
diagnosing and monitoring progression and treatment
response of MCI and early dementia.
562 ASLAM ET AL.These estimates also vary significantly depending on the definitions
used in different studies. For example, a large population‐based study
of older‐aged individuals in the United Kingdom7 reported prevalence
estimates of individuals not classified from current MCI definitions
were variable (range, 2.5‐41.0%). In addition, the rates of progression
from MCI to dementia varied from 3.7% to 30.0%.7
Evidence from neuropathological and neuroimaging studies sug-
gests that biological changes associated with dementia occur long
before the onset of symptoms.8 This has given rise to the concept
of mild cognitive impairment (MCI), which is the state between the
cognitive changes of normal ageing and early dementia.9-11 Mild
cognitive impairment refers to the clinical condition used to describe
people whose cognitive function is below that of the normal popula-
tion for their educational level and age but who do not have any loss
of functional abilities or skills.11-14 It is a heterogeneous state, with
possible trajectories including Alzheimer disease (AD), Lewy body
dementias, and even reversion to normal cognitive functioning.15
The difference between MCI and early dementia is based on the
level of cognitive decline and pattern of change in mood and behav-
iour. Individuals diagnosed with early dementia present with multiple
cognitive deficits, and their memory loss is sufficient to impact every-
day social and occupational functioning. Among the 4 most common
medical conditions causing dementia are AD, vascular conditions,
frontotemporal atrophy, and Lewy body disease. Irrespective of the
primary reason, the cognitive prognosis for people with most types
of dementia is usually poor.16,17
There are a number of pen‐and‐paper–based tools as suitable
tests for screening people for cognitive impairment, for example, the
General Practitioner Assessment of Cognition, 6‐item Cognitive
Impairment Test, and Mini‐cog assessment instrument.18,19 There are
different pen‐and‐paper tests used to aid diagnosis by specialists for
MCI and early dementia, for example, the Dementia Toolkit for Effec-
tive Communication,20 Montreal Cognitive Assessment,21 and Saint
Louis University Mental Status.22 However, these specialist tests can
be expensive and time‐consuming.23 More recently, several automated
tests have been developed,24,25 which may be uniquely suited to early
detection of changes in cognition, by, for example, covering a wider
range of ability to precisely record accuracy and speed of response
with a level of sensitivity not possible in standard administrations.23
The rationale for this review is to determine whether automated
computerised tests for cognitive impairment have the potential to con-
tribute to early diagnosis and simplify the current method of monitor-
ing progression and treatment response compared with standard
clinical practice.2 | METHODS
A systematic review was performed to describe the diagnostic accu-
racy of automated tests to detect MCI and early dementia as well as
investigate their role in monitoring disease progression and response
to treatment. The methodology and reporting of this review followed
the guidance set out by the Cochrane Handbook for Diagnostic Test
Accuracy Reviews.26 See Appendix S1 found in the Supporting Infor-
mation for an abbreviation list.2.1 | Criteria for considering studies for this review
Any study assessing the diagnostic accuracy of automated
computerised tests to diagnose or monitor MCI or early dementia
against a reference standard was considered for inclusion. Case studies
and qualitative studies were excluded. Studies or diagnostic tools
published in a non‐English language were also excluded.
2.1.1 | Participants
Participants were people with MCI or early dementia diagnosed by any
recognised diagnostic standard.
2.1.2 | Index tests
The index tests considered for inclusion were automated
computerised tests of cognitive impairment, which can either be self‐
administered or interviewer administered.
2.1.3 | Reference standard
The reference standard for this review is the clinical diagnosis of MCI
and early dementia using a diagnostic criteria, for example, the Interna-
tional Classification of Diseases2 edition 10 and the Diagnostic and
Statistical Manual of Mental Disorders editions 4 and 5 (DSM‐IV and
DSM‐V, respectively).27 It is recognised that clinical diagnosis itself has
a degree of variability, but this is not unique to dementia studies and
does not invalidate the basic diagnostic test accuracy approach.2.2 | Search methods for identification of studies
The following electronic databases were searched from January
2005 to August 2015 to identify studies for inclusion: Medline,
Embase, Cochrane database, Institute for Scientific Information,
PsycINFO, and ProQuest for dissertations and theses (see Appendix
S2 found in the Supporting Information for search strategy in
Medline). Through citation tracking, one study from 2001 was
included since it reported on a computerised tests currently in use
in clinical practise. The number of references retrieved from
ASLAM ET AL. 563different databases is provided in Appendix S3 found in the
Supporting Information, and were managed in Endnote X7.2.3 | Selection of studies
Two reviewers independently screened all relevant titles and abstracts
and full‐text articles for inclusion. Any disagreements were resolved by
discussion with a third reviewer.2.4 | Data extraction and management
Data extraction forms were developed and piloted in an Excel
spreadsheet by using 2 of the included studies. Data on study
design, population characteristics, and outcomes were extracted by
one reviewer and independently checked for accuracy by a second
reviewer, with disagreements resolved through discussion with a
third reviewer when necessary. The extracted data included informa-
tion on the reference standard, index test, cut‐off points, and the
measures of diagnostic test accuracy including sensitivity, specificity,
receiver operating characteristic curve, and the area under the curve
(AUC) for discriminating amongst MCI, early dementia, and cogni-
tively healthy individuals.2.5 | Assessment of methodological quality
The methodological quality of the included studies was assessed by
one reviewer and independently checked for accuracy by a second
reviewer using the Quality Assessment of Diagnostic Accuracy Studies
tool,28 which is recommended by the Cochrane Diagnostic Test Accu-
racy Reviews Guidelines.29 This tool is designed to evaluate the risk of
bias and applicability of primary diagnostic accuracy studies using sig-
nalling questions in 4 domains: patient selection, index test, reference
standard, and flow and timing.2.6 | Statistical analysis and data synthesis
An Excel spreadsheet was used to construct 2 × 2 tables of index test
performance. The measures of index test performance were recorded
by the number of true‐positive, true‐negative, false‐positive, and
false‐negative, sensitivity, and specificity values of MCI and early
dementia. The sensitivity and specificity values with 95% confidence
intervals, positive and negative predictive values (PPV and NPV,
respectively), and positive and negative likelihood ratios (LR+ and LR
−, respectively) were calculated when not reported in the studies.
Out of authors of all the included studies approached with a request
for specific sensitivity and specificity data, only 2 provided these data.
It was not possible to perform a meta‐analysis because of non-
comparable data; the study designs varied, the cut‐off points for the
primary outcome measure were heterogeneous, and the summary sta-
tistics were often inconsistently reported. A narrative synthesis of the
results of the included studies was conducted.2.7 | Patient and public involvement
An advisory group comprising clinicians and service users guided the team
during the review. A call for participation was sent through frontlinegroups, for example, Alzheimer's Society and Dementia UK, to identify
people interested in giving feedback on the results of the review and on
the final report. The review team took guidance from these agencies
and INVOLVE30 for planning and facilitating the meetings.3 | RESULTS
3.1 | Results of the search
The electronic search was conducted in August 2015, and 18 796
records were retrieved, of which 399 articles were shortlisted for
full‐text assessment (Figure 1). The comprehensive search strategy
was necessary because indexing of diagnostic accuracy studies is poor.
In total, 16 studies met the inclusion criteria for detecting MCI and
early dementia. No studies met the review inclusion criteria for moni-
toring progression or treatment response in MCI or early dementia,
and therefore, there is no further mention of monitoring disease pro-
gression in the results section.
In addition to the 16 included studies, 4 trials were identified dur-
ing hand searching (Appendix S4 found in the Supporting Information).
The authors of these studies were approached by email and telephone
for results, but no responses were received. The summary of the
included 16 studies is presented in Table 1; there were 7 cohort stud-
ies, 7 case‐control studies, and 2 cross‐sectional studies.40,43 Seven of
the 16 included studies evaluated the use of automated computerised
tests to detect MCI alone, 2 studies reported results for early demen-
tia, 6 studies reported results for combined MCI/early dementia, and 1
study reported on cognitive impairment with a co‐morbidity, eg,
human immunodeficiency virus (HIV)–associated neurocognitive disor-
ders (HANDs).43 Two different reference standards were used for MCI
in these studies, 9 studies used the Petersen criteria, and 4 studies
used clinical diagnosis with a battery of neurocognitive tests. The ref-
erence standard for early dementia varied across different studies, 2
studies used National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer's Disease and Related Disor-
ders Association Alzheimer's Criteria,42,46 2 studies used DSM‐
IV,33,34 1 study used the DSM‐V criteria,39 2 studies used clinical diag-
nosis with neurocognitive tests,36,46 and 1 study used the Clinical
Dementia Rating score.41
3.1.1 | Findings
The diagnostic accuracy of 11 automated computerised tests for
the detection of MCI and/or early dementia without co‐morbidities
was evaluated in 15 studies and 1 study with co‐morbidity.43 The
details of the index tests are summarised in Table 2. Pooling of data
from these 16 studies was considered inappropriate since there
were few studies evaluating the same index test in the same
population, and it was only possible to extract 2 × 2 data from 5
of the 16 studies.
3.2 | Studies reporting on diagnostic accuracy
outcomes with a 2 × 2 table
There were 5 studies that reported diagnostic accuracy outcomes in a
2 × 2 table as described inTable 3. Two studies reported the diagnostic
Records identified through 
database searching  
(n=13,352) 
Full-text articles assessed for eligibility  
(n=399) 
Additional records identified 
through ProQuest, handsearching 
and citation tracking 
(n=5,444) 
Records after duplicates removed  
(n=13,542) 
Records screened on title and abstract  
(n=13,542)
Records excluded  
(n=13,143) 
Full-text articles excluded 
(n=383) 
Paper-based test 116 
Wrong study design 59 
Wrong indication – other 55 
Not an evaluation of the 
automated test 31 
Wrong patient population 32 
Systematic review 23 
Literature review 20 
Wrong intervention 16 
Wrong outcomes 15 
Automated test not in English 
9 
Timeline 4 
Duplicate 3 
Records included in diagnostic accuracy 
review  
(n=16) 
FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta‐Analyses flow diagram
564 ASLAM ET AL.accuracy outcomes for MCI, 3 studies reported outcomes for early
dementia, and 1 study reported combined outcomes for both MCI
and early dementia.3.2.1 | Mild cognitive impairment
Juncos‐Rabadan et al35 evaluated 3 different visual episodic memory
tests included in the Cambridge Neuropsychological Test Automated
Battery (CANTAB); these memory tests were Pattern Recognition
Memory, Delayed Matching to Sample, and Paired Associated Learn-
ing. The overall sensitivity and specificity for the 3 visual episodic
memory tests were moderate at 79.7% and 76.3%, respectively. The
overall AUC for the different visual episodic tests was not reported,
but ranged from 0.623 (Delayed Matching to Sample) to 0.747 (Paired
Associated Learning), showing poor ability to discriminate between the
MCI group and the non‐MCI group. This test had a high overall PPV of
71.4%; this means 71.4% of the people who tested positive for MCI
with the index test actually had MCI according to the reference stan-
dard. Similarly, the overall NPV for this test was 83.3%, meaning that
83.3% of people who tested negative for MCI on the index test did
not have MCI. This test had a low overall LR+ of 3.4, which shows a
low likelihood of the test to establish the presence of disease. It also
had a low overall LR− of 0.3, which shows a low likelihood of the test
to establish the absence of disease.The study by Saxton et al44 evaluated the Computer Assessment
of Memory and Cognitive Impairment (CAMCI) and reported good
sensitivity (86%) and exceptional specificity (94%). The reported AUC
(0.91) was also very high.3.2.2 | Early dementia
The CANTAB Paired Associated Learning (CANTAB‐PAL) was
evaluated in 2 of the studies. Junkikla et al36 reported high sensitivity
(81.8%) and specificity (97.2%) and an AUC of exceptional discrimina-
tion (0.914) for early dementia.
The study by O'Connell et al42 reported poor sensitivity (67.6%)
and high specificity (100%) and an AUC of moderate discrimination
(0.780) between the early‐dementia group and non–early‐dementia
group.
Mundt et al41 assessed the Computer Automated Telephone
System and reported moderate sensitivity (79.17%) and high specific-
ity (83.8%) for this test.3.2.3 | MCI/early dementia
One study evaluated CANTAB‐PAL. The authors reported high
sensitivity (96.9%) and high specificity (80.8%) with an AUC of good
discrimination (0.897) between the MCI/early‐dementia group and
non‐MCI/early‐dementia group.
T
A
B
LE
1
St
ud
y
an
d
pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
St
ud
y
C
o
nd
it
io
n
C
o
un
tr
y,
Se
tt
in
g
N
M
ea
n
ag
e,
ye
ar
s
(S
D
,r
an
ge
)
G
en
de
r
(M
al
e
%
)
M
ea
n
E
du
ca
ti
o
n
,y
(S
D
,R
an
ge
)
In
d
ex
T
es
t
N
am
e
R
ef
er
en
ce
T
es
t
A
hm
ed
et
al
3
1
M
C
I
U
ni
te
d
K
in
gd
o
m
3
5
(c
o
nt
ro
l:
2
0
,M
C
I:
1
5
)
C
o
nt
ro
l:
7
7
.4
(4
)
C
o
nt
ro
l:
5
5
.0
C
on
tr
ol
:1
4.
7
(2
.9
)
C
A
N
S‐
M
C
I
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
th
e
P
et
er
se
n
cr
it
er
ia
P
ri
m
ar
y
ca
re
(O
xf
o
rd
O
P
T
IM
A
st
ud
y)
a
M
C
I:
8
0
.9
(7
.2
)
M
C
I:
3
3
.3
M
C
I:
1
3
.1
(3
)
D
e
Ja
ge
r
et
al
3
2
M
C
I
U
ni
te
d
K
in
gd
o
m
1
1
9
(c
o
nt
ro
l:
9
8
,M
C
I:
2
1
)
C
o
nt
ro
l:
7
7
.1
8
(5
.9
)
N
R
U
nc
le
ar
C
o
gS
ta
te
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
b
at
te
ry
o
f
n
eu
ro
co
gn
it
iv
e
te
st
s
C
o
m
m
un
it
y
M
C
I:
8
1
.9
5
(5
.4
)
D
o
ni
ge
r
et
al
3
3
M
C
I
U
ni
te
d
St
at
es
1
6
1
(c
o
nt
ro
l:
7
1
,M
C
I:
5
8
,m
ild
A
D
:3
2
)
E
nt
ir
e
gr
o
up
:
7
6
.0
(8
.2
)
E
nt
ir
e
gr
o
up
:
3
7
.5
E
nt
ir
e
gr
o
up
:
1
3
.3
(3
.6
)
M
in
ds
tr
ea
m
s
(a
br
id
ge
d)
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
th
e
P
et
er
se
n
cr
it
er
ia
fo
r
M
C
I
an
d
D
SM
‐I
V
fo
r
d
em
en
ti
a
T
er
ti
ar
y
ca
re
M
C
I/
m
ild
de
m
en
ti
a
M
em
o
ry
cl
in
ic
D
w
o
la
tz
ky
et
al
3
4
M
C
I
C
an
ad
a/
Is
ra
el
9
8
(c
o
nt
ro
l:
3
9
,
M
C
I:
3
0
,
m
ild
A
D
:
2
9
)
C
o
nt
ro
l:
7
3
.4
1
(8
.0
0
)
C
o
nt
ro
l:
3
3
.3
C
o
nt
ro
l:
1
4
.9
5
(3
.5
)
M
in
ds
tr
ea
m
s
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
th
e
P
et
er
se
n
cr
it
er
ia
fo
r
M
C
I
an
d
D
SM
‐I
V
fo
r
m
ild
A
D
M
ild
A
D
2
te
rt
ia
ry
ca
re
m
em
o
ry
cl
in
ic
s
M
C
I:
7
7
.1
5
(6
.4
3
)
M
C
I:
5
6
.7
M
C
I:
1
3
.0
7
(2
.8
6
)
M
ild
A
D
:
8
0
.5
5
(4
.9
1
)
M
ild
A
D
:
4
4
.8
M
ild
A
D
:
1
1
.3
1
(2
.8
5
)
Ju
nc
o
s‐
R
ab
ad
an
et
al
3
5
aM
C
I
Sp
ai
n
1
6
2
(c
o
nt
ro
l:
8
5
,m
da
‐M
C
I:
2
9
,s
da
‐M
C
I:
4
8
)
C
o
nt
ro
l:
6
2
.2
5
(8
.2
6
,5
0
‐8
2
)
A
ll
pa
rt
ic
ip
an
ts
:
3
6
.4
C
o
nt
ro
l:
1
0
.8
3
(5
,2
‐2
1
)
C
A
N
T
A
B
‐R
(P
R
M
,D
M
S,
an
d
P
A
L)
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
n
eu
ro
co
gn
it
iv
e
te
st
s
an
d
th
e
A
lb
er
t
cr
it
er
ia
an
d
P
et
er
so
n
cr
it
er
ia
fo
r
aM
C
I
P
ri
m
ar
y
ca
re
m
da
‐M
C
I:
7
1
.6
8
(7
.7
4
,5
4
‐8
7
)
m
da
‐M
C
I:
1
0
.0
6
(3
.9
9
,3
‐2
0
)
sd
a‐
M
C
I:
6
8
.0
2
(9
.0
4
,5
0
‐8
4
)
sd
a‐
M
C
I:
9
.8
3
(3
.9
6
,2
‐2
0
)
Ju
nk
ki
la
et
al
3
6
aM
C
I/
m
ild
/
pr
o
ba
bl
e
de
m
en
ti
a
F
in
la
nd
5
8
(c
o
nt
ro
l:
2
2
,
aM
C
I:
1
7
,A
D
:
1
9
)
C
o
nt
ro
l:
7
0
(4
.4
8
,6
5
‐8
0
)
C
o
nt
ro
l:
3
6
.3
6
C
o
nt
ro
l:
1
0
(3
.2
5
)
C
A
N
T
A
B
‐P
A
L
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
th
e
P
et
er
se
n
cr
it
er
ia
an
d
n
eu
ro
co
gn
it
iv
e
te
st
s
M
ild
/p
ro
ba
bl
e
de
m
en
ti
a
H
o
sp
it
al
aM
C
I:
7
3
(6
.3
,6
1
‐8
3
)
aM
C
I:
6
4
.7
aM
C
I:
8
(3
)
A
D
:7
3
(6
.7
6
,
6
1
‐8
3
)
A
D
:
2
6
.3
5
A
D
:
8
(2
.8
8
)
K
in
gs
bu
ry
et
al
3
7
M
C
I
A
us
tr
al
ia
1
4
0
(c
o
nt
ro
l:
9
5
,M
C
I:
3
0
,d
ep
re
ss
ed
:
1
5
)
C
o
nt
ro
l:
6
8
.8
5
(7
.9
6
,5
3
‐8
9
)
C
o
nt
ro
l:
3
7
C
o
nt
ro
ls
:
4
.9
3
(1
.7
1
)
C
o
gn
iS
cr
ee
n
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
th
e
P
et
er
se
n
cr
it
er
ia
C
o
m
m
un
it
y
M
C
I:
7
7
.6
2
(7
.4
5
,5
1
‐8
7
)
M
C
I:
4
3
M
C
I:
3
.0
7
(1
.7
1
)
M
em
o
ry
cl
in
ic
U
nc
le
ar
w
ha
t
is
m
ea
su
re
d
K
lu
ge
r
et
al
3
8
M
C
I
U
ni
te
d
St
at
es
1
0
1
(c
o
nt
ro
l:
3
9
,
M
C
I:
1
9
,p
ro
ba
bl
e
A
D
:
1
7
,n
o
di
ag
no
si
s:
2
5
)
C
o
nt
ro
l:
6
4
(1
1
)
N
R
N
R
C
o
m
pu
te
ri
se
d
te
st
(n
o
na
m
e)
D
ia
gn
o
se
d
b
y
a
co
n
se
n
su
s
o
f
at
le
as
t
2
cl
in
ic
ia
n
s
E
ar
ly
de
m
en
ti
a
M
em
o
ry
cl
in
ic
M
C
I:
7
2
(1
0
)
P
ro
ba
bl
e
A
D
:
7
8
(9
)
Li
ch
te
nb
er
g
et
al
3
9
M
C
I/
ea
rl
y
de
m
en
ti
a
U
ni
te
d
St
at
es
1
0
2
(c
o
nt
ro
l:
5
5
,
M
C
I:
1
1
,m
ild
de
m
en
ti
a:
3
6
)
A
ll
pa
rt
ic
ip
an
ts
:
7
9
.3
(6
.6
)
A
ll
pa
rt
ic
ip
an
ts
:
4
6
.1
A
ll
pa
rt
ic
ip
an
ts
:
1
3
.5
(2
.9
)
C
ST
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
th
e
P
et
er
se
n
cr
it
er
ia
;
cl
in
ic
al
d
ia
gn
o
si
s
o
f
d
em
en
ti
a
u
si
n
g
D
SM
‐V
Sp
ec
ia
lis
ed
ge
ri
at
ri
c
cl
in
ic
M
ar
uf
f
et
al
4
0
M
C
I
A
us
tr
al
ia
7
6
6
(c
o
nt
ro
l:
6
5
9
,
aM
C
I:
1
0
7
)
C
o
nt
ro
l:
6
9
.5
(6
.6
)
C
o
nt
ro
l:
4
2
.2
C
o
nt
ro
l:
1
2
a
(9
‐1
5
)
C
B
B
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
th
e
P
et
er
so
n
cr
it
er
ia
P
ri
m
ar
y
ca
re
M
C
I:
7
5
.7
(7
.5
)
M
C
I:
4
9
.5
M
C
I:
1
2
a
(9
‐1
5
)
M
un
dt
et
al
4
1
D
em
en
ti
a
U
ni
te
d
St
at
es
1
1
6
(c
o
nt
ro
l:
7
4
,
m
ild
de
m
en
ti
a:
4
2
)
A
ll
pa
rt
ic
ip
an
ts
:
7
6
.7
(7
.0
,5
6
‐9
3
)
A
ll
pa
rt
ic
ip
an
ts
:
3
6
.7
A
ll
pa
rt
ic
ip
an
ts
:
1
3
.3
(3
,6
‐2
2
)
C
o
m
pu
te
r‐
au
to
m
at
ed
te
le
ph
o
ne
sc
re
en
in
g
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
C
D
R
sc
o
re
Sp
ec
ia
lis
ed
ge
ri
at
ri
c
cl
in
ic
(C
o
n
ti
n
u
es
)
ASLAM ET AL. 565
T
A
B
LE
1
(C
o
nt
in
ue
d)
St
ud
y
C
o
nd
it
io
n
C
o
un
tr
y,
Se
tt
in
g
N
M
ea
n
ag
e,
ye
ar
s
(S
D
,r
an
ge
)
G
en
de
r
(M
al
e
%
)
M
ea
n
E
du
ca
ti
o
n
,y
(S
D
,R
an
ge
)
In
d
ex
T
es
t
N
am
e
R
ef
er
en
ce
T
es
t
O
'C
o
nn
el
le
t
al
4
2
P
ro
ba
bl
e
A
D
Ir
el
an
d
5
0
(c
o
nt
ro
l:
1
6
,
pr
o
ba
bl
e
A
D
:3
4
)
C
o
nt
ro
l:
7
2
.6
(7
.7
)
C
o
nt
ro
l:
1
2
.5
N
R
C
A
N
T
A
B
‐P
A
L
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
th
e
N
IN
C
D
S‐
A
D
R
D
A
cr
it
er
ia
M
em
o
ry
cl
in
ic
P
ro
ba
bl
e
A
D
:
7
3
(5
.9
)
P
ro
ba
bl
e
A
D
:3
2
.4
R
o
se
nt
ha
le
t
al
4
3
H
A
N
D
U
ni
te
d
St
at
es
5
5
(H
IV
+
co
nt
ro
ls
:1
6
,
H
A
D
:
3
9
)
H
IV
+
co
nt
ro
ls
:
4
5
.4
(6
)
H
IV
+
co
nt
ro
ls
:
7
5
.0
H
IV
+
co
nt
ro
ls
:
1
2
.3
(1
.8
)
C
A
M
C
I
m
o
di
fi
ed
H
A
N
D
ca
te
go
ry
u
si
n
g
th
e
F
ra
sc
at
ic
ri
te
ri
a
G
en
er
al
cl
in
ic
al
re
se
ar
ch
cl
in
ic
H
A
D
:
4
8
.3
(6
.3
)
H
A
D
:
7
1
.8
H
A
D
:
1
2
.6
(2
.1
)
Sa
xt
o
n
et
al
4
4
M
C
I
U
ni
te
d
St
at
es
5
2
4
(c
o
nt
ro
l:
2
9
6
,M
C
I:
2
2
8
)
C
o
nt
ro
l:
7
1
.8
4
(5
.9
5
)
M
C
I:
3
7
.7
C
o
nt
ro
l1
3
.7
4
(2
.6
9
)
C
A
M
C
I
C
lin
ic
al
d
ia
gn
o
si
s
b
y
co
n
se
n
su
s
u
si
n
g
b
at
te
ry
o
f
n
eu
ro
co
gn
it
iv
e
te
st
s
an
d
fu
n
ct
io
n
al
an
d
m
ed
ic
al
in
fo
rm
at
io
n
P
ri
m
ar
y
ca
re
an
d
co
m
m
un
it
y
M
C
I:
7
5
.1
8
(6
.7
6
)
C
o
nt
ro
l:
3
2
.8
M
C
I:
1
3
.1
0
(2
.6
1
)
T
ie
rn
ey
et
al
4
5
M
C
I
C
an
ad
a
2
6
3
C
o
m
pl
et
ed
w
it
ho
ut
as
si
st
an
ce
:
7
8
.7
(6
.9
)
A
ll
pa
rt
ic
ip
an
ts
:
4
1
.4
C
o
m
pl
et
ed
w
it
ho
ut
as
si
st
an
ce
:
1
5
.2
(3
.2
)
C
A
M
C
I
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
b
at
te
ry
o
f
n
eu
ro
co
gn
it
iv
e
te
st
s
T
er
ti
ar
y
ca
re
N
R
C
o
m
pl
et
ed
w
it
h
as
si
st
an
ce
:
8
1
.8
(6
.5
)
C
o
m
pl
et
ed
w
it
h
as
si
st
an
ce
:
1
3
.9
(4
.0
)
V
ac
an
te
et
al
4
6
M
C
I
U
ni
te
d
K
in
gd
o
m
7
8
(c
o
nt
ro
l:
4
0
,
M
C
I:
2
0
,e
ar
ly
A
D
:
1
8
)
Tr
ad
it
io
na
lv
er
si
on
Tr
ad
it
io
na
lv
er
si
on
Tr
ad
it
io
na
lv
er
si
on
T
P
T
C
lin
ic
al
d
ia
gn
o
si
s
u
si
n
g
th
e
P
et
er
se
n
cr
it
er
ia
C
o
nt
ro
l:
7
4
.7
(7
.7
8
)
C
o
nt
ro
l:
5
0
C
o
nt
ro
l:
1
5
.8
5
(3
.3
6
)
M
C
I:
7
8
.3
(8
.4
)
M
C
I:
6
0
M
C
I:
1
5
.9
(3
.3
2
)
E
ar
ly
A
D
:
7
3
.6
7
(6
.2
8
)
E
ar
ly
A
D
:
6
6
.7
E
ar
ly
A
D
:
1
5
(3
.0
4
)
E
ar
ly de
m
en
ti
a
P
ri
m
ar
y
ca
re
(O
xf
o
rd
O
P
T
IM
A
st
ud
y)
a
N
ov
el
ve
rs
io
n
N
ov
el
ve
rs
io
n
N
ov
el
ve
rs
io
n
C
o
nt
ro
l:
7
3
.6
7
(7
.1
4
)
C
o
nt
ro
l:
4
5
C
o
nt
ro
l:
1
6
.3
5
(3
.1
8
)
M
C
I:
7
9
.7
(6
.0
7
)
M
C
I:
6
0
M
C
I:
1
5
(2
.6
6
)
E
ar
ly
A
D
:
7
7
.2
2
(4
.9
4
)
E
ar
ly
A
D
:7
7
.8
E
ar
ly
A
D
:1
6
.1
1
(2
.9
7
)
A
bb
re
vi
at
io
ns
:A
D
,A
lz
he
im
er
di
se
as
e;
aM
C
I,
am
ne
st
ic
m
ild
co
gn
it
iv
e
im
pa
ir
m
en
t;
C
A
M
C
I,
C
o
m
pu
te
r
A
ss
es
sm
en
t
o
f
M
ild
C
o
gn
it
iv
e
Im
pa
ir
m
en
t;
C
A
N
S‐
M
C
I,
C
o
m
p
u
te
r‐
A
d
m
in
is
te
re
d
N
eu
ro
p
sy
ch
o
lo
gi
ca
lS
cr
ee
n
fo
r
M
ild
C
o
gn
it
iv
e
Im
pa
ir
m
en
t;
C
A
N
T
A
B
,C
am
br
id
ge
N
eu
ro
ps
yc
ho
lo
gi
ca
lT
es
t
A
ut
o
m
at
ed
B
at
te
ry
;C
A
N
T
A
B
‐P
A
L,
C
am
br
id
ge
N
eu
ro
ps
yc
ho
lo
gi
ca
lT
es
t
A
ut
o
m
at
ed
B
at
te
ry
P
ai
re
d
A
ss
o
ci
at
ed
Le
ar
n
in
g;
C
B
B
,C
o
gS
ta
te
B
ri
ef
B
at
te
ry
;
C
D
R
,C
lin
ic
al
D
em
en
ti
a
R
at
in
g
Sc
al
e;
C
ST
,C
o
m
pu
te
ri
se
d
Se
lf
‐T
es
t;
D
M
S,
D
el
ay
ed
M
at
ch
in
g
to
Sa
m
pl
e;
D
SM
‐I
V
,D
ia
gn
os
ti
c
an
d
St
at
is
ti
ca
lM
an
ua
lo
f
M
en
ta
lD
is
or
de
rs
ed
it
io
n
4
;
H
A
D
,H
IV
‐a
ss
o
ci
at
ed
d
em
en
ti
a;
H
A
N
D
,
H
IV
‐a
ss
o
ci
at
ed
ne
ur
o
co
gn
it
iv
e
di
so
rd
er
;
H
IV
+
,
hu
m
an
im
m
un
o
de
fi
ci
en
cy
vi
ru
s;
N
R
,
no
t
re
po
rt
ed
;
M
C
I,
m
ild
co
gn
it
iv
e
im
pa
ir
m
en
t;
m
da
‐M
C
I,
m
ul
ti
pl
e‐
d
o
m
ai
n
am
n
es
ti
c
m
ild
co
gn
it
iv
e
im
p
ai
rm
en
t;
N
IN
C
D
S‐
A
D
R
D
A
,
N
at
io
na
lI
ns
ti
tu
te
o
f
N
eu
ro
lo
gi
ca
la
nd
C
o
m
m
un
ic
at
iv
e
D
is
o
rd
er
s
an
d
St
ro
ke
an
d
th
e
A
lz
he
im
er
's
D
is
ea
se
an
d
R
el
at
ed
D
is
o
rd
er
s
A
ss
o
ci
at
io
n;
O
P
T
IM
A
,O
xf
o
rd
P
ro
je
ct
to
In
ve
st
ig
at
e
M
em
o
ry
an
d
A
ge
in
g;
P
A
L,
P
ai
re
d
A
ss
o
-
ci
at
ed
Le
ar
ni
ng
;
P
R
M
,P
at
te
rn
R
ec
o
gn
it
io
n
M
em
o
ry
;
sd
a‐
M
C
I,
si
ng
le
‐d
o
m
ai
n
am
ne
st
ic
m
ild
co
gn
it
iv
e
im
pa
ir
m
en
t;
T
P
T
,T
he
P
la
ci
ng
T
es
t.
a I
t
is
un
cl
ea
r
as
to
w
he
th
er
th
es
e
co
ho
rt
s
w
er
e
in
de
pe
nd
en
t
to
ea
ch
o
th
er
.
b
M
ed
ia
n.
566 ASLAM ET AL.
T
A
B
LE
2
In
de
x
te
st
de
ta
ils
St
ud
y
T
es
t
N
am
e
C
o
gn
it
iv
e
D
o
m
ai
ns
T
es
te
d
D
et
ai
ls
o
f
T
es
t
P
la
tf
o
rm
U
se
d
T
im
e
(m
in
)
M
et
h
o
d
o
f
A
d
m
in
is
tr
at
io
n
A
hm
ed
et
al
3
1
C
A
N
S‐
M
C
I
M
em
o
ry
D
es
kt
o
p
co
m
pu
te
r,
a
to
uc
h
sc
re
en
sy
st
em
w
it
h
bo
th
o
ra
l
(lo
ud
sp
ea
ke
rs
)
an
d
o
n
sc
re
en
in
st
ru
ct
io
ns
3
0
Se
lf
‐a
d
m
in
is
te
re
d
La
ng
ua
ge
V
is
uo
sp
at
ia
l
R
es
ea
rc
h
er
in
ro
o
m
E
xe
cu
ti
ve
fu
nc
ti
o
n
D
e
Ja
ge
r
et
al
3
2
C
o
gS
ta
te
M
em
o
ry
In
te
rn
et
A
p
p
ro
xi
m
at
el
y
2
0
Se
lf
‐a
d
m
in
is
te
re
d
E
xe
cu
ti
ve
fu
nc
ti
o
n
A
tt
en
ti
o
n
P
ra
ct
ic
e
se
ss
io
n
w
it
h
a
p
sy
ch
o
lo
gi
st
P
ro
ce
ss
in
g
sp
ee
d
D
o
ni
ge
r
et
al
3
2
M
in
ds
tr
ea
m
s
(a
br
id
ge
d)
M
em
o
ry
C
o
m
pu
te
r
an
d
m
o
us
e
3
0
Se
lf
‐a
d
m
in
is
te
re
d
E
xe
cu
ti
ve
fu
nc
ti
o
n
V
is
uo
sp
at
ia
l
P
ra
ct
ic
e
se
ss
io
n
M
o
to
r
sk
ill
s
D
w
o
la
tz
ky
et
al
3
4
M
in
ds
tr
ea
m
s
M
em
o
ry
D
es
ig
ne
d
fo
r
us
e
w
it
h
o
ld
er
pe
o
pl
e.
M
o
us
e
w
it
h
th
e
nu
m
be
r
pa
d
o
n
th
e
ke
yb
o
ar
d
(s
im
ila
r
to
th
e
te
le
ph
o
ne
ke
yp
ad
)
4
5
Se
lf
‐a
d
m
in
is
te
re
d
E
xe
cu
ti
ve
fu
nc
ti
o
n
P
ra
ct
ic
e
se
ss
io
n
w
it
h
fe
ed
b
ac
k
p
ri
o
r
to
te
st
in
g
V
is
uo
sp
at
ia
l
V
er
ba
l
R
es
ea
rc
h
as
si
st
an
t
A
tt
en
ti
o
n
In
fo
rm
at
io
n
pr
o
ce
ss
in
g
M
o
to
r
sk
ill
s
Ju
nc
o
s‐
R
ab
ad
an
et
al
3
5
C
A
N
T
A
B
‐R
(P
R
M
,
D
M
S,
an
d
P
A
L)
M
em
o
ry
T
o
uc
h
sc
re
en
co
m
pu
te
r
N
R
Se
lf
‐a
d
m
in
is
te
re
d
R
es
ea
rc
h
er
p
re
se
n
t
Ju
nk
ki
la
et
al
3
6
C
A
N
T
A
B
‐P
A
L
M
em
o
ry
T
o
uc
h
sc
re
en
co
m
pu
te
r
N
R
Se
lf
‐a
d
m
in
is
te
re
d
K
in
gs
bu
ry
et
al
3
7
C
o
gn
iS
cr
ee
n
M
em
o
ry
La
pt
o
p,
he
ad
se
t
w
it
h
m
ic
ro
ph
o
ne
2
0
‐4
0
Se
lf
‐a
d
m
in
is
te
re
d
E
xp
er
im
en
te
r
in
ro
o
m
K
lu
ge
r
et
al
3
8
C
o
m
pu
te
ri
se
d
te
st
(n
o
na
m
e)
M
em
o
ry
La
pt
o
p
1
2
‐1
5
Se
lf
‐a
d
m
in
is
te
re
d
P
ra
xi
s
N
am
in
g
Sc
re
en
in
g
te
st
fo
r
co
m
p
u
te
r
co
m
p
et
en
cy
E
xe
cu
ti
ve
fu
nc
ti
o
n
Li
ch
te
nb
er
g
et
al
3
9
C
ST
Le
ar
ni
ng
In
te
rn
et
ba
se
d,
in
te
rf
ac
e
w
it
h
bo
th
w
ri
tt
en
an
d
o
ra
li
ns
tr
uc
ti
o
ns
1
5
Se
lf
‐a
d
m
in
is
te
re
d
M
em
o
ry
K
ey
b
o
ar
d
p
ro
fi
ci
en
cy
te
st
E
xe
cu
ti
ve
fu
nc
ti
o
n
A
d
m
in
is
te
re
d
b
y
gr
ad
u
at
e
p
sy
ch
o
lo
gy
st
u
d
en
ts
M
ar
uf
f
et
al
4
0
C
B
B
M
em
o
ry
D
es
kt
o
p
co
m
pu
te
r,
ye
s/
no
bu
tt
o
n
at
ta
ch
ed
th
ro
ug
h
U
SB
po
rt
1
0
Se
lf
‐a
d
m
in
is
te
re
d
V
er
b
al
in
st
ru
ct
io
n
s
b
y
su
p
er
vi
so
r
P
ra
ct
ic
e
se
ss
io
n
M
un
dt
et
al
4
1
C
o
m
pu
te
r‐
au
to
m
at
ed
te
le
ph
o
ne
sc
re
en
in
g
M
em
o
ry
St
an
da
rd
to
uc
h
to
ne
te
le
ph
o
ne
s
1
1
‐1
5
Se
lf
‐a
d
m
in
is
te
re
d
Sp
at
ia
l(
au
di
to
ry
)
E
xe
cu
ti
ve
fu
nc
ti
o
n
o
ri
en
ta
ti
o
n
R
es
ea
rc
h
er
p
ro
vi
d
ed
as
si
st
an
ce
in
d
ia
lli
n
g
th
e
n
u
m
b
er
La
ng
ua
ge
O
'C
o
nn
el
le
t
al
4
2
C
A
N
T
A
B
‐P
A
L
M
em
o
ry
T
o
uc
h
sc
re
en
co
m
pu
te
r
1
0
N
R
(C
o
n
ti
n
u
es
)
ASLAM ET AL. 567
T
A
B
LE
2
(C
o
nt
in
ue
d)
St
ud
y
T
es
t
N
am
e
C
o
gn
it
iv
e
D
o
m
ai
ns
T
es
te
d
D
et
ai
ls
o
f
T
es
t
P
la
tf
o
rm
U
se
d
T
im
e
(m
in
)
M
et
h
o
d
o
f
A
d
m
in
is
tr
at
io
n
R
o
se
nt
ha
le
t
al
4
3
C
A
M
C
I
m
o
di
fi
ed
M
em
o
ry
T
ab
le
t
w
it
h
st
yl
us
2
5
Se
lf
‐a
d
m
in
is
te
re
d
A
tt
en
ti
o
n
E
xe
cu
ti
ve
fu
nc
ti
o
n
pr
o
ce
ss
in
g
sp
ee
d
Sa
xt
o
n
et
al
4
4
C
A
M
C
I
M
em
o
ry
D
es
kt
o
p
co
m
pu
te
r
A
p
p
ro
xi
m
at
el
y
2
0
Se
lf
‐a
d
m
in
is
te
re
d
A
tt
en
ti
o
n
E
xe
cu
ti
ve
fu
nc
ti
o
n
pr
o
ce
ss
in
g
sp
ee
d
T
ie
rn
ey
et
al
4
5
C
A
M
C
I
M
em
o
ry
T
ab
le
t
co
m
pu
te
r
3
0
Se
lf
‐a
d
m
in
is
te
re
d
,
so
m
e
re
q
u
ir
ed
re
se
ar
ch
er
as
si
st
an
ce
A
tt
en
ti
o
n
E
xe
cu
ti
ve
fu
nc
ti
o
n
pr
o
ce
ss
in
g
sp
ee
d
V
ac
an
te
et
al
4
6
T
P
T
M
em
o
ry
C
o
m
pu
te
r
2
0
Se
lf
‐a
d
m
in
is
te
re
d
In
cl
u
d
in
g
p
ra
ct
ic
e
p
ag
es
A
bb
re
vi
at
io
ns
:
C
A
M
C
I,
C
o
m
pu
te
r
A
ss
es
sm
en
t
o
f
M
ild
C
o
gn
it
iv
e
Im
pa
ir
m
en
t;
C
A
N
S‐
M
C
I,
C
o
m
pu
te
r‐
A
dm
in
is
te
re
d
N
eu
ro
ps
yc
ho
lo
gi
ca
l
Sc
re
en
fo
r
M
ild
C
o
gn
it
iv
e
Im
p
ai
rm
en
t;
C
A
N
T
A
B
,C
am
b
ri
d
ge
N
eu
ro
p
sy
ch
o
lo
gi
ca
l
T
es
t
A
ut
o
m
at
ed
B
at
te
ry
;C
A
N
T
A
B
‐P
A
L,
C
am
br
id
ge
N
eu
ro
ps
yc
ho
lo
gi
ca
lT
es
t
A
ut
o
m
at
ed
B
at
te
ry
P
ai
re
d
A
ss
o
ci
at
ed
Le
ar
ni
ng
;C
B
B
,C
o
gS
ta
te
B
ri
ef
B
at
te
ry
;C
ST
,C
o
m
p
u
te
ri
se
d
Se
lf
‐T
es
t;
D
M
S,
D
el
ay
ed
M
at
ch
in
g
to
Sa
m
-
pl
e;
N
R
,n
o
t
re
po
rt
ed
;
P
A
L,
P
ai
re
d
A
ss
o
ci
at
ed
Le
ar
ni
ng
;
P
R
M
,P
at
te
rn
R
ec
o
gn
it
io
n
M
em
o
ry
;
T
P
T
,T
he
P
la
ci
ng
T
es
t.
568 ASLAM ET AL.3.3 | Studies reporting on diagnostic accuracy
outcomes without a 2 × 2 table
The authors of 11 studies reported diagnostic accuracy outcomes for 9
different index tests without using 2 × 2 data as tabulated in Table 4.
Instead, they calculated optimal sensitivity and specificity values using
receiver operating characteristic curve analysis.
3.3.1 | Mild cognitive impairment
Eight studies reported the diagnostic accuracy outcomes for MCI.
Ahmed et al evaluated Computer‐Administered Neuropsychological
Screen for Mild Cognitive Impairment and reported high sensitivity
(89.0%) and moderate specificity (73.0%) with an AUC of 0.867,
which shows a good ability to discriminate between the MCI group
and the non‐MCI group. Tierney et al evaluated the CAMCI test
and reported a high sensitivity (80.0%) and a moderate specificity
(74.0%); the authors did not report AUC values. Maruff et al evalu-
ated the CogState Brief Battery (CBB). The CogState Brief Battery
has 2 composite scores for 4 tasks: psychomotor function, attention
function, learning memory, and working memory. The psychomotor/
attention function had poor discrimination since its AUC was 0.67. It
also had poor sensitivity (41.1%) but high specificity (85.7%). The
AUC for the learning/working memory was 0.91, which shows
exceptional ability to discriminate between the MCI group and the
non‐MCI group. It also had high sensitivity (80.4%) and high specific-
ity (84.7%). The overall sensitivity, specificity, and AUC were not
reported.
3.3.2 | Early dementia
Dwolatzky et al34 and Doniger et al33 both assessed the Mindstreams
computerised cognitive testing. Only Doniger et al reported results
relating to early dementia. They evaluated an abridged version of
Mindstreams with an overall AUC of 0.886, which showed a good abil-
ity to discriminate between the early‐dementia group and the non–
early‐dementia group.
3.3.3 | MCI/early dementia
Kluger et al evaluated an automated computerised test, which did not
have a specific name. The authors reported an AUC of 0.97, which
shows exceptional ability to discriminate between early dementia and
healthy controls.
Doniger et al reported an overall AUC of 0.823, which showed a
good ability to discriminate between the cognitively healthy group
and the cognitive unhealthy group. The AUC values for individual test
results ranged from 0.671 to 0.773.
Lichtenberg et al39 reported sensitivity and specificity values
(80.0% and 87.0%, respectively), PPV (88.0%), and NPV (79.0%).
3.3.4 | HIV‐associated neurocognitive disorders
One study43 evaluated diagnostic accuracy of an automated
computerised test that included people with cognitive impairment with
co‐morbidities. This study examined the HAND and used the auto-
mated test CAMCI. The CAMCI test assessed multiple domains with
different tasks. The study examined a range of diagnostic accuracy
outcomes but did not report the values for all of them.
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ASLAM ET AL. 5713.3.5 | Methodological quality
The methodological quality of the included studies was assessed using
the Quality Assessment of Diagnostic Accuracy Studies tool as
summarised in Figure 2.
The risk‐of‐bias criterion for patient selection was high for 7 studies
because a case‐control study design had not been avoided (see
Appendix S6 found in the Supporting Information). Seven studies were
judged to be at unclear risk in the index test criteria for risk of bias since
the threshold values for the index tests were not prespecified. There
was high concern regarding the applicability of the index test for all of
the studies because the interpretation of the index test was different
from the review question, since it is not possible to establish diagnosis
of MCI and early dementia using automated computerised tests in
isolation; specialist expertise is necessary to establish a diagnosis.
The reference standard domain for the risk of bias was unclear in 8
studies since it was not possible to ascertain whether reference standard
results were interpreted without knowledge of the results of the index
tests. All but one study38 were judged to have low concern for applica-
bility regarding the reference standard since it used a consensus of 2
clinicians' opinions as the reference standard. In the flow and timing
domain for the risk of bias, a judgement of unclear risk of bias was given
to 2 studies35,43 since attrition or timing was not described in the papers.
However, 14 studies were assessed as being at low risk because all
patients had received the same reference standard and all patients were
included in the analysis. There was a high concern in the domains of
applicability for 16 studies. Of the 16 studies, only 1 was judged to be
at low of risk of bias across the 4 domains examined39; despite this,
the overall quality of the included studies was considered to be good.3.4 | Patient and public involvement
Data from the included studies were presented and discussed with a ser-
vice user. The structure of the meeting is described in Appendix S5
found in the Supporting Information. The service user thought that all
of the index text domains needed to be tested to enable a comprehen-
sive overview of any suspected cognitive impairment. His view was that
more information on key domains would help clinicians and patients
address the challenges faced by patients with MCI or early dementia.
The service user raised concerns about the age of the study participants
since there were no tests that assessed cognitive impairment in people
over the age of 90 years. Another concern was the effect of little or
no education on the ability to perform well on the test. The importance
of the index tests being user‐friendly and acceptable to patients was also
highlighted. He also stated a preference for desktop computers over
touch screen test, in case a patient had tremors. He also highlighted
the importance of ensuring that the colour palette in visual components
of the tests had a sharp contrast because it is likely that older people will
have problems with their eyesight. He also stated that some people
might become frustrated with tests that lasted longer than 40 minutes.4 | DISCUSSION
In assessing the diagnostic accuracy of a test, an index test with high
specificity is preferable for diagnosis, and high sensitivity is preferred
FIGURE 2 Risk of bias and applicability
concerns summary [Colour figure can be
viewed at wileyonlinelibrary.com]
572 ASLAM ET AL.for screening.47 When patients are diagnosed with MCI or early demen-
tia, an index test with both high sensitivity and specificity is needed to
be able to appreciate a distinctive pattern of cognitive impairment in
MCI and early dementia. This distinctive pattern of cognitive impairment
distinguishes the cognitive impairment caused by another disease
process, eg, cognitive impairment as presented in depression or HIV.
A number of studies included in this review were not conducted in
samples representative of the usual clinical population in which these
tests might be used (eg, patients visiting the memory clinics with a
mix of MCI and dementia of various aetiologies and the “worried well”
and depressed patients) but were conducted in convenience samples
of patients with limited diagnoses (mostly MCI and AD). This, along
with the lack of reliable evidence to support one test over the other,
makes it difficult to draw a clear picture of the diagnostic accuracy of
the index tests in this review.There was some disparity in how the studies were reported; for
example, all of the index tests, except 4, were used as screening tests,
yet the authors reported outcomes for diagnostic accuracy. It is also
not clear from reviewing the included studies whether these
computerised tests ought to be used in primary or secondary care. In
the United Kingdom, some primary care practices take part in “case
finding” for dementia, for example, targeting “high‐risk” groups (eg,
older adults or patients with high vascular risk, learning disability, or
Parkinson disease), and hospital staff undertake brief cognitive assess-
ments during all acute admissions for older adults.
The pen‐and‐paper tests currently used in clinical practice not only
help clinicians differentiate between normal cognition, MCI, and
dementia20-22 but also assist in staging severity of illness. The CAN-
TAB test was the only automated test that could stage severity.35,36,42
But 2 of the 3 CANTAB‐PAL studies36,42 had very small sample sizes
ASLAM ET AL. 573(58 and 50, respectively), and the slightly larger study35 only tested the
domain of visual episodic memory. The time taken to complete these
computerised tests is not clear in the case of CANTAB‐PAL and
depending on the version of Mindstreams, ranged from 30 to
45 minutes.33 In contrast, the paper‐based tests range from 7 to
10 minutes in their application.20-22 Concern for the time it takes to
complete the tests was raised in the service user feedback; the user
pointed out the possibility of people becoming frustrated with tests
that lasted for more than 40 minutes, especially if they are not familiar
with using technology. The data in the included papers also did not
describe the time needed for training the assessor and the need for a
specialist for scoring.
An important point to consider is that current diagnosis of patients
with MCI and early dementia is based on clinical judgement and med-
ical history as well as on the results of paper‐based cognitive tests.
Automated tests cannot be used in isolation or substituted for clinical
judgement. Even with prespecified cut‐off values for a particular pop-
ulation, any cognitive testing measure alone is insufficient to render a
diagnostic classification.
None of the previously conducted relevant reviews in this area
conducted a diagnostic accuracy review.23,48,49 They were narrative
reviews that provided a summary of the battery of tests used and rated
this evidence on validity and reliability, comprehensiveness, and usabil-
ity. This review focused on computerised tests that were self‐adminis-
tered and had a minimum level of involvement from professionals. In
line with the findings of this review, the authors of the other reviews
concluded that there is significant difference in automated
computerised tests, and hence, they must be judged on a case‐by‐case
basis.23
More research is required to establish stable cut‐off points for
each automated test used to diagnose patients with MCI or early
dementia. An important consideration is testing the cut‐off points
in specific patient populations, for example, in patients of different
age groups or education levels and from different geographical
regions.
Another area for future research is providing more information on
the costs of automated tests and include time for training, administra-
tion, and scoring of the different tests, as these are important factors
for their use in routine clinical practice. This information is currently
absent in the published studies describing automated tests used to
diagnose or monitor people with MCI or early dementia. No studies
reporting on outcomes relating to monitoring progression of disease
could be identified, which highlights a difficulty in the current method
of monitoring progression and treatment response compared with
standard clinical practice.4.1 | Strengths of this review
The search strategy for this review was extensive. The methodological
rigour of the review process was enhanced by the use of 2 assessors to
perform citation screening, quality assessment, and data extraction/
checking. All of the primary study authors were contacted and asked
to fill in the contingency tables. A patient and public involvement exer-
cise was also conducted.4.2 | Weaknesses of the review
This review is limited in part by the number of included studies for the
same automated computerised test. Because of noncomparable data
relating to the index test, it was not appropriate to pool the data.
Another limitation with the studies is the lack of comparative results
across the different domains being examined.5 | CONCLUSIONS
It is difficult to draw a clear picture of the diagnostic accuracy of
automated computerised tests to establish a diagnosis of MCI or
early dementia in this review because there is currently insufficient
evidence to support the use of one test over the other. Further
research is required to examine the cut‐off points for the diagnosis
of MCI and early dementia when using automated tests. These test
scores do not always relate with medical history and more impor-
tantly with functioning. The suitability of these tests also depends
on their cost, time needed for training the assessor, time needed
for the administration of the test, and the need for a specialist for
scoring.
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